Yes, although this Senate hearing was heavy on HCQ, there were many positives for leronlomab.
1. Education on the virulogic vs immunologic phase
2. Emphasis on more approval of therapeutics
3. Outpatient (m/m) population is becoming a crowded space. Leronlimab is standing alone (or in the lead spot) in s/c.
1. Education on the virulogic vs immunologic phase
2. Emphasis on more approval of therapeutics
3. Outpatient (m/m) population is becoming a crowded space. Leronlimab is standing alone (or in the lead spot) in s/c.
2